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Inflammation plays a major pathological role in spinal cord injury
(SCI). Although antiinflammatory treatment using the glucocorti-
coid methyprednisolone sodium succinate (MPSS) improved out-
comes in several multicenter clinical trials, additional clinical ex-
perience suggests that MPSS is only modestly beneficial in SCI and
poses a risk for serious complications. Recent work has shown that
erythropoietin (EPO) moderates CNS tissue injury, in part by
reducing inflammation, limiting neuronal apoptosis, and restoring
vascular autoregulation. We determined whether EPO and MPSS
act synergistically in SCI. Using a rat model of contusive SCI, we
compared the effects of EPO [500–5,000 unitskg of body weight
(kg-bw)] with MPSS (30 mgkg-bw) for proinflammatory cytokine
production, histological damage, and motor function at 1 month
after a compression injury. Although high-dose EPO and MPSS
suppressed proinflammatory cytokines within the injured spinal
cord, only EPO was associated with reduced microglial infiltration,
attenuated scar formation, and sustained neurological improve-
ment. Unexpectedly, coadministration of MPSS antagonized the
protective effects of EPO, even though the EPO receptor was
up-regulated normally after injury. These data illustrate that the
suppression of proinflammatory cytokines alone does not neces-
sarily prevent secondary injury and suggest that glucocorticoids
should not be coadministered in clinical trials evaluating the use of
EPO for treatment of SCI.
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The emotional and economic costs of spinal cord injury (SCI)are large, especially for the long-term nursing care necessi-
tated by profound disability. Despite multiple therapeutic ap-
proaches that target different aspects of the pathophysiologic
cascade contributing to SCI, there have been no major advances
in clinical care that reliably attenuate injury or restore function.
Despite initial clinical data suggesting that treatment using
MPSS within 8 h of injury provides benefit (1), the current
consensus is that MPSS offers, at best, limited improvement and
may actually cause harm, e.g., acute corticosteroid myopathy (2)
or infection (3, 4), particularly in high-risk patients. Although
great promise exists for the potential use of stem cell transplan-
tation, much additional preclinical work is required before
moving into clinical trials (reviewed by Kulbatski et al. in ref. 5).
Clearly, other therapeutic alternatives merit current exploration.
From a pathophysiological perspective, SCI has historically been
divided into two distinct phases. Primary (mechanical) injury
directly disrupts tissues but, in the acute phase, frequently causes
only limited cell death surrounding the lesion epicenter. However,
vigorous inflammation initiated as a response to primary injury
subsequently causes extensive demyelination, tissue edema, and
irreversible cell loss (reviewed by Kwon in ref. 6). As a general
response to serious injury, the hypothalamic–adrenal axis is acti-
vated, and endogenous cortisol is secreted to potentially control
excessively destructive inflammation. As a cortisol substitute, the
synthetic glucocorticoid methyprednisolone sodium succinate
(MPSS) attenuates spinal cord damage in preclinical models by
reducing lipid peroxidation produced by free-radical and reactive
oxygen species generated by cellular metabolism, especially within
the milieu of ischemia followed by reperfusion (7). MPSS has also
been reported to reduce proinflammatory cytokine production and
tissue edema (8), inducible nitric oxide synthase activity, neuronal
apoptosis (9), free-radical formation, and release of excitatory
amino acids and vasoactive molecules and also provides beneficial
modulation of calcium and sodium transcellular fluxes.
However, several unresolved issues exist in consideration of
MPSS for the treatment of SCI. For example, in cats, the observed
dose–response is an inverted U-shaped curve, with higher doses
(e.g., 60 mgkg) being ineffective (reviewed byHall and Springer in
ref. 10).Other species, e.g., rodents, have received less attention, but
the results suggest a different outcome, with only a small window
of opportunity for reducing tissue injury and with no improvement
in motor outcome (11). Additional detrimental effects of glucocor-
ticoids have been clearly documented, including potentiation of
ischemic (12) and inflammatory (13) neuronal injury and potent
suppression of neurotrophic factors, e.g., glial-derived neurotrophic
factor (14).
The cytokine erythropoietin (EPO) (previously known for its
hormonal effects on the bone marrow), which maintains an ade-
quate circulating red-cell mass, also functions as a markedly potent,
locally produced molecule ameliorating metabolic stress in many
tissues (reviewed by Brines and Cerami in ref. 15). Studies have
demonstrated robust EPO-mediated protection of the spinal cord
from ischemia in the rabbit (16) ormechanical trauma in the rabbit,
rat, and mouse (17–19). EPO mediates tissue protection via mul-
tiple, interacting pathways (reviewed by Ghezzi and Brines in ref.
20), including a reduction of both apoptotic cell death and the
reactive increases in proinflammatory cytokines (21), mobilization
of endothelial progenitor cells, promotion of angiogenesis (22) and
healing (23), restoration of vascular autoregulation (24–26), and
reduction of lipid peroxidation (19).
Although amarked protection in SCI byEPOhas been observed,
more needs to be learned about the therapeutic window, optimal
site of administration, and dose-ranging characteristics. In antici-
pation of the study of EPO in human clinical trials, we assessed
these parameters using a well defined mechanical-injury model in
the rat. Because of the current clinical use of MPSS in SCI, we also
evaluated the effects of this compound in the absence or presence
of EPO, determining the extent of anatomical injury, hindlimb
motor function 1 month after injury, and concentrations of key
proinflammatory cytokines that are important mediators of sec-
ondary injury within the spinal cord.
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A wide therapeutic temporal and dosage range for EPO was
observed, and, although both agents reduced the production of
proinflammatory cytokines equivalently, MPSS was completely
ineffective in preventing secondary injury. Unexpectedly, coadmin-
istration of MPSS with EPO resulted in a complete loss of EPO-
mediated tissue protection, despite fully suppressed proinflamma-
tory cytokine levels.
Materials and Methods
Animals. Adult Sprague–Dawley rats (Charles River Laboratories)
weighing 240–260 g were used. Animals were kept under standard
housing conditions (22  2°C, 65% humidity, and lights from 6:00
a.m. to 8:00 p.m.) and were fed a standard dry diet; water was
available ad libitum. All experimental protocols were approved by
the Animal Review Committee of the University of Milan and the
Kenneth S. Warren Institute and met the Italian guidelines for
laboratory animals [which conform to the European Communities
Directive of November, 1986 (86609EEC) and the Guide for the
Care and Use of Laboratory Animals, National Research Council].
Serum EPO Levels.For determining pharmacokinetics, animals were
injected with recombinant human (rh)EPO (Dragon Pharmaceu-
ticals, Vancouver, BC, Canada) at the dose and route indicated in
the text. Serum samples were serially withdrawn via the tail vein and
human EPO concentration determined by using an ELISA that
does not cross-react with rat EPO (Quantiquine, R & D Systems).
SCI with UTS-Impactor and Drug Treatment. Traumatic SCI was
performed by means of the UTS-impactor, which is fully described
in the supporting information for ref. 17. The core of the UTS-
impactor is a 2.3-mm end-diameter stainless steel rod that is
precisely driven into the spinal cord with a specified force and
displacement. The movement and impact is monitored by means of
a miniaturized piezoelectric dynamometer present within a section
of the impacting rod and linked to a computer that drives the device
and records and manages the data. The impounding piston was
positioned 1 mm above the exposed cord at T9 and set for an
excursion of 3 mm. A force of 1 Newton for 1 second was applied,
followed by an automatic return of the impaction rod.Animals were
maintained under halothane anesthesia and positioned over a mat
kept at the temperature of 38°C and, before awakening, were
treated with buprenorphine [0.03 mgkg of body weight (kg-bw)]
for pain and penicillin G (10,000 unitskg-bw) as an antimicrobial
agent. Each experimental group contained at least 18 animals.
After SCI, the rats were housed two per cage and underwent
manual bladder evacuation three times daily. rhEPO (Epoietin
Alpha, Ortho Biotech, Milan) was administered as a single treat-
ment within 30 min after injury. Methylprednisolone sodium suc-
cinate (Sigma) was administered at a dose of 30 mgkg-bw by i.p.
injection. Notably, a dose of 60 mgkg proved to be lethal, killing
all of the animals treated (n  8) within the first week after
induction of SCI.
Functional Assessment. All outcome measures were obtained in
blinded fashion by four investigators and averaged. Neurological
function was evaluated at 24 h after injury and then twice a week
thereafter, by open-field testing using the methodology of Basso,
Beattie, and Bresnahan (27).
Histology and Immunocytochemistry.At the end of the experimental
period, animals were anesthetized by inhalation of halothane and
perfused with 4% paraformaldehyde in isotonic PBS at pH 7.4 by
transcardial perfusion. The spinal cord encompassing the full injury
site was postfixed (24 h) with the same paraformaldehyde-
containing solution, and segments of the spinal cord were embed-
ded in paraffin and 8-m sections cut transversely. Every 20th
section was stained with hematoxylin and eosin. One cross section
containing the lesion epicenter and the total T9-segment cavitation
was analyzed by using computer-assisted image analysis (NIH IM-
AGE, National Institutes of Health, Bethesda) through a Leica DG
100 camera mounted on a Leica microscope). The extent of
cavitation was calculated as the area of cavitated tissue divided by
the area of the total cross-section at the level of the injury (five per
experimental group). Vibratome sections (40 m) were also col-
lected onto glass slides and processed for immunocytochemistry.
Primary antibodies for glial fibrillary acidic protein (GFAP) and
ED-1 (1:500; Chemicon) were applied overnight at 4°C and incu-
bated for 3 h at room temperature with FITC-conjugated rabbit
anti-mouse antibody (Chemicon). Vibratome sections were incu-
bated with a polyclonal antibody to EPO (H-162; 1:300; Santa Cruz
Biotechnology) and processed according to the peroxidase–
antiperoxidase method.
Cytokine ELISA. At the indicated times, spinal cord tissue was
homogenized and sonicated (Branson Sonifier 250) in a 7.4 pH
buffer solution containing 10 mM Tris, 0.032 mM sucrose, 0.5 mM
EDTA, 2 mM EGTA, 1 mM PMSF, 10 gml leupeptin, and 10
gml aprotinin. The processing was performed at 4°C. Proteins
were determined by the Lowry–Ciocalteau technique (28). The
tissue concentration of inflammatory cytokines [macrophage in-
flammatory protein (MIP)-2 (homologue of human IL-8), TNF-,
IL-6, and IL-1] were assayed at the site of injury by means of
specific ELISA kits (BioSource Europe, Nivelles, Belgium) follow-
ing the manufacturer’s instructions. At least six animals per group
were included for analysis.
Western Blotting. Proteins were prepared from spinal cord tissue
obtained from rostral, lesion epicenter, and caudal regions, and
protein-concentration determination was performed according to
the Lowry–Ciocalteau technique (28). Proteins (75 g) were sep-
arated on a 10% polyacrylamide gel and transferred onto nitrocel-
lulose membranes. Membranes were subsequently incubated with
a polyclonal antibody directed against EPO receptor (EPOR)
(H-194; 1:200, Santa Cruz Biotechnology) and bands visualized by
using the Kodak Image Station 440.
Statistical Analysis.Data are expressed as the mean SD.Multiple
group comparisons of the differences in quantitativemeasurements
were made by ANOVA, followed by Dunnett’s t test (two-tailed).
Statistical significance was accepted for a P  0.05 level.
Results
Serum EPO Levels. A dose of 1,000 unitskg-bw rhEPO, adminis-
tered via the tail vein as a bolus injection, reached a peak level of
2,070 ngml at the first sample point (15 min) and decayed slowly
thereafter (Fig. 1). In contrast, an i.p. dose of 1,000 unitskg-bw
reached a peak of 80 ngml at about 2 h and then slowly
decreased. A dose of 500 unitskg-bw i.v. peaked at 100 ngml,
and a dose of 5,000 unitskg-bw via either route reached equivalent
serum levels only after 15 h (data not shown).
Fig. 1. Pharmakokinetics of rhEPO (5,000 unitskg-bw) administered via the
i.v. or i.p. routes (mean of three animals per group).
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Inflammatory Response at the Lesion Epicenter. At baseline, scat-
tered white matter cells and large pyramidal motoneurons ex-
pressed EPO (Fig. 2A). Four weeks after SCI, the EPO immuno-
reactivity was greatly increased in white matter astrocytes, whereas
surviving neurons appeared unchanged (Fig. 2B). The staining
intensity of neurons and astrocytes did not appear to change after
an i.p. dose of 5,000 unitskg-bwEPO (Fig. 2B). In Fig. 2C, a typical
section of the posttraumatic cavity is also visible, and its size is
markedly reduced by EPO treatment (Fig. 2B). Four weeks after
SCI, quantitative evaluation of the percentage of spared tissue at
the lesion epicenter showed a significant reduction by EPO treat-
ment but not if MPSS was applied alone or in addition to EPO
(Table 1). Posttraumatic gliosis and scar formation (data not
shown) was also reduced by EPO treatment. In the normal spinal
cord, GFAP-positive cells are mainly located around the central
canal and are only sparsely distributed in the white matter (Fig. 3
A–C). After injury, however, many GFAP-positive cells are present
throughout the white and gray matter and around the cavitation
(Fig. 3 D–F). Treatment with rhEPO (5,000 unitskg-bw i.p.)
greatly reduced gliosis (Fig. 3 G–I) and inflammatory-cell recruit-
ment into the site of injury: The number of cells expressing ED-1
(i.e., microglia) within the lesion epicenter after 7 days was mark-
edly reduced by EPO treatment (Fig. 4).
Tissue Cytokine Concentrations. Spinal cord concentrations of in-
flammatory cytokines determined by ELISA within the lesion
epicenter at 1, 2, or 7 days after SCI (Fig. 5) exhibited time-
dependent increases after injury, with MIP-2 (IL-8) increasing
markedly within the first day and maintained up to 7 days. Treat-
ment withMPSS or EPO was associated with a gradual decrease in
MIP-2 levels beginning 2 days after SCI. MIP-2 is a recruitment
signal for leukocytes, and histological evaluation at day 7 was
remarkable for an almost complete absence of these inflammatory
cells (Fig. 4), suggesting that secondary injury would also be
reduced.
TNF- peaked by 2 days and subsequently decreased slightly but
remained elevated at much higher levels, compared with the
controls, for at least 7 days after injury. Both EPO and MPSS
administration prevented these increases (Fig. 5). IL-6 also peaked
within 2 days but then decreased rapidly. Both EPO and MPPS
reduced the maximum IL-6 levels to that of the control. The
posttraumatic increase of IL-1 occurred in the first day and was
counteracted by both agents.
Recovery of Hindlimb Function. Open-field locomotor testing con-
firmed previous studies indicating that single doses of EPO im-
proved recovery of hindlimb function for at least 4weeks postinjury.
The beneficial effects ofEPO(5,000 unitskg-bw i.p.), administered
within 30 min of lesioning, were obvious between 4 and 8 days after
SCI and reached a plateau between 12 and 16 days (Fig. 6 Left).
When treatment was delayed by 24 or 48 h, only a transient
improvement was observed during the early posttraumatic stages of
recovery, and, in both cases, motor function was not significantly
Fig. 2. Localization of EPO-expressing neurons and astrocytes at 4 weeks after SCI in vibratome sections of spinal cords at 3 mm rostral from the center of the
lesion site by immunoperoxidase technique from control (A) and lesioned rats with (B) or without (C) rhEPO (5,000 unitskg-bw i.p.) treatment. In unlesioned
rats subjected to only a laminectomy, positive labeling is observed in neurons throughout thegraymatter and astrocytes in thewhitematter (A). A posttraumatic
cavity (*) is present in lesioned rats treated with saline. (C) Astrocytes are more intensively stained, especially in the dorsal columns, whereas neurons are not.
(B) In rats treated with rhEPO, the cavity is markedly reduced, and astrocytes hyperexpress EPO.






Saline 42.1  2.3 49.9  3.6
EPO 56.2  4.0* 66.4  3.0*
MPSS 43.4  5.2 48.2  6.7
EPO plus MPSS 42.7  3.2 51.4  4.8
EPO at the dose of 5,000 unitskg-bw i.p. andMPSS 30mgkg-bw i.p. *, P
0.01 compared with saline, MPSS, and EPO plus MPSS. Data are given as
means  SD.
Fig. 3. Immunolocalization of GFAP-positive cells at 3 mm rostral from the
center of the SCI lesion site by immunofluorescence in vibratome sections of
spinal cords obtained 4 weeks after SCI from control (A–C) and lesioned rats
with (G–I) or without (D–F) rhEPO treatment. (A–C) In control spinal cords,
some positive cells are present close to the meninges of the dorsal horn (dh)
(A), around the central canal (cc) (B), and in the ventral white matter (vh) and
meninges (C). (D–F) In lesioned saline-treated rats, GFAP-positive cells are
present throughout the cord andaround theposttraumatic cavity (DandE) (*)
and in the ventral white matter (F). (G–I) Treatment with rhEPO greatly
attenuates the GFAP expression in the injured cord.











different from saline-treated controls after 16 days (Fig. 6 Center).
A lower dose of EPO, administered by means of an i.p. injection
within 30 min of SCI, was less effective. A dose of 500 unitskg-bw
i.p. yielded a smaller but significant improvement (Fig. 6 Right).
When EPO was administered via the i.v. route, the minimum
effective dose decreased to 500 unitskg-bw, with lower doses being
ineffective (Fig. 6Right).MPSS administration in combination with
EPO, however, affected greatly the efficacy of EPO, because it
failed to enhance the rate of hindlimb recovery (Fig. 7A), showing
only a transient improvement (similar to the delayed treatment).
MPPS alone also did not affect the rate of recovery of function and
was identical to saline.Western blotting performed forEPORusing
proteins obtained adjacent to the lesion epicenter showed marked
increases at all levels examined 1 day after injury, maintained for at
least an additional 24 h (Fig. 7B). Treatment with MPSS did not
affect EPOR protein abundance.
Discussion
EPO and its nonerythropoietic derivatives have been shown to be
remarkably effective in tempering injury in diverse tissues and
organs (reviewed by Brines and Cerami in ref. 15). For EPO in
experimental stroke, the presence of the blood–brain barrier has
required high doses, in the range of 500–5,000 unitskg-bw
administered i.v. or i.p. for effective triggering of neuroprotection.
Similarly, the data obtained here and our previous observations
(17) show that rhEPO, administered i.p., is effective in SCI at a
minimum effective dose of 500 unitskg-bw. The fact that high
doses of EPO i.v. or i.p. are therapeutic when administered within
30min, despite amuch slower rise of serum levels after i.p. injection,
is consistent with a broad therapeutic temporal window in which
delayed dosing is still effective in SCI. A dose of 500 unitskg-bw
of EPO, administered i.v., that peaked at 100 ngml was as
efficacious as a dose of 5,000 unitskg-bw i.p. that produced serum
concentrations of50–80 ngml. In contrast, lower doses of EPO
administered either i.v. or i.p. were ineffective, suggesting that peak
serum concentrations of 50 ngml are required for significant
protection. Unlike EPO’s action in erythropoiesis, in which the
area-under-the-curve predicts biological efficacy (29) attainment of
a minimum peak concentration appears to be critical for tissue
protection.
We have shown that a wide therapeutic time window exists for
the nonerythropoietic analogue of EPO (carbamylated EPO),
administered in a multiple-dosage regimen after compressive
SCI (30) and for a single dose of EPO, administered i.v. at 5,000
unitskg-bw (31). In this study, the temporal window for a single
dose of EPO administered via the i.p. route appears narrower.
Although an initial improvement was noted for animals treated
with EPO, it was transient, and, after 14 days, the slope of the
recovery curve lessened, and the motor score at 1 month was not
different from the saline group. This observation suggests that
traumatic impact to the spinal cord triggers processes that cannot
be modulated by a single dose of exogenous EPO administered
with a delay of 12 h. The qualitatively different type of injury
(with an especially prominent vascular component) produced by
the aneurysm-clip model appears to lack this critical-injury
component, because a single dose can be delayed for 24 h
without a significant loss in efficacy (31).
Fig. 4. Immunolocalization of ED-1-positive cells at 2 mm rostral from the
center of the SCI lesion site by immunofluorescence in cryostat sections of
spinal cords from lesioned rats 7 days after SCI with (EPO) or without (SALINE)
rhEPO treatment. The number of ED-1-positive cells is greatly reduced
throughout the lesion site in rhEPO-treated rats.
Fig. 5. Cytokine profiles within the spinal cord after injury show that both EPO and MPSS suppress proinflammatory cytokine production to an equivalent
degree. (Upper Left)MIP-2. (UpperRight) TNF-. (Lower Left) IL-1. (LowerRight) IL-6. LAM, laminectomyalone.*,P0.05;**,P0.01;***,P0.001 (compared
with PBS).
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A complicated interplay of pro- and antiinflammatory molecules
orchestrates the pathophysiology of the spinal cord after injury.
Within the first hours, neutrophils appear (32), with lymphocytes
and microglia only later mobilized into the injury site (at 24–48 h).
Waves of oligodendrocyte apoptosis begins later (peaking at about
day 8) and are completed by 12–14 days (33, 34).Our data show that
even a single dose of EPO can markedly reduce the influx of
microglia (ED-1-positive cells) into the lesion site within 1 week.
The presence of microglia is associated with cavitation and marked
scarring, as we have observed for the saline-treated animals, and
was not seen in the EPO-treatment groups.
Much attention has focused on the potential key roles of the
proinflammatory cytokines TNF-, IL-1, and IL-6 for amplifica-
tion of damage after a CNS injury (35). In our experiments, the
TNF- and IL-6 in untreated animals peaked by day 2 and
thereafter declined, even without treatment. The observed peaks
are delayed compared with the reports in other studies of a range
of 1–6 h of neurons and microglia, respectively (36, 37). Further-
more, Pan et al. (38) have shown rapid induction (minutes) of
proinflammatory cytokine mRNAs in SCI arising from the spinal
cord itself. An explanation for these differences is currently lacking
but could depend on the severity of injury and, therefore, the
pathophysiological mechanism of cytokine production. Despite
obvious differences in peak cytokine production, there is a con-
sensus in the literature that MPSS suppresses inflammation (re-
viewed in ref. 39).
However, it is interesting that, althoughMPSSmarkedly reduced
cytokine concentrations, both locally within the epicenter andmore
distally, no improvement in outcome was observed in our studies.
Thus, permanent injury does not invariably depend on the presence
of inflammatory processes. It is especially surprising that MPSS-
mediated suppression of IL-6 was not associated with an improved
motor score, because changes of this cytokine have been associated
with a parallel modulation of injury in experimental SCI (40, 41).
It should be noted that, in contrast to MPSS, other experimental
treatments attenuating the acute inflammatory response, e.g., the
hydroxymethylglutaryl CoA reductase inhibitor atorvastatin (42) or
antithrombin (43), among others, show significant benefits in
preclinical models.
When MPSS was coadministered with a dose of EPO otherwise
sufficient to promote recovery, an early improvement in motor
score was observed over the first 2 days, similar to what is seen with
delayed administration of EPO alone, suggesting that MPSS neu-
tralized early EPO-mediated protective responses, likely nonin-
flammatory actions of EPO. A number of potential explanations
exist. For example, MPSS might blunt the up-regulation of EPOR,
a critical mediator of responsiveness to injury, for both endogenous
and exogenous EPO. On the basis of the EPORWestern blot data
obtained from the injured spinal cord, EPOR is present in this
model not only at baseline but increases after the impaction in a
similar manner, with or without MPSS. Of note, however, the
antibody used detects the EPOR monomer, whereas our work
suggests that tissue protection is mediated by a heteromeric recep-
tor consisting of the EPOR and the  common subunit receptor
(18) of IL-3. Protein analysis based on EPOR alone, therefore,
would not detect changes of the  common subunit abundance.
Alternatively, MPSS could interfere with assembly of the heter-
complex transducing tissue protection. Another receptor-based
explanation could be that, although MPSS decreases cytokine
expression, it might not do the same for cytokine receptors.
Therefore, trace levels of cytokines could still signal biologically.
Currently, there are no data available to evaluate this possibility.
SCI is associated with an early loss of vascular autoregulation,
which, if antagonized, leads to a rapid motor recovery (44, 45) that
Fig. 6. Open-field motor scores after injury show dose-, time-, and route-dependency of EPO. (Left) For single doses delivered i.p. both 5,000 unitskg-bw and
500 unitskg-bw were significantly better than saline, whereas 100 unitskg-bw was not. (Center) Although EPO (5,000 unitskg-bw) administered up to 48 h
after injurywas associatedwith a significantly bettermotor score for thefirst 3weeks after injury, by 28 days, 24- and 48-h delays in treatmentwere not different
from saline. (Right) EPO administered i.v. at a lower dose of 500 unitskg-bw was significantly better than the same dose administered i.p.
Fig. 7. MPSS neutralizes EPO-mediated spinal cord protection. (A) MPSS
antagonizes the protective effects of EPO in recovery of open-field motor
scores. Although early recovery was significantly better than saline, by 3
weeks, animals receiving both MPSS and EPO were not different from those
receiving saline. (B) Immunoblotting for EPOR within the spinal cord at 24 or
48 h after a sham injury (laminectomy and impactor positioning only) (CTR)
revealed the most pronounced expression of EPOR protein in the rostral (R),
lesion site (L), and caudal (C) portions of the cord. Subsequent to impaction
injury, EPOR immunoreactivity increased markedly at the three levels exam-
ined. No differences were noted between MPSS- versus saline (SAL)-treated
animals.











is very similar temporally to what has been observed after EPO
administration. In other preclinical injurymodels, e.g., the spasm of
the basilar artery induced by subarachnoid hemorrhage (46, 47) or
the splanchnic-artery constriction in the setting of septic shock (24),
are reversed by single doses of EPO. It is notable that high-dose
glucocortoid administration has been associated with vascular
dysfunction (reviewed by Yand and Zhang in ref. 48). A major
mechanism appears to be disordered nitric oxide production and
function (49, 50).
Furthermore, MPSS might increase the clearance of EPO from
the vasculature, for example, by augmenting renal excretion. This
explanation appears very unlikely, because an EPO analogue with
an exceedingly short half-life (several minutes) is very effective
when administered as a single bolus immediately after compressive
injury of the spinal cord (51). Although high-dose MPSS could
inhibit the sympathetic discharge after an injury (52) (which,
secondarily, could suppress IL-10-mediated antiinflammatory ef-
fects) (53, 54), there is no evidence supporting this possibility.Other
potential endocrine-mediated systemic effects ofMPSS are possible
and will require evaluation.
High-dose glucocorticoid administration has been shown to
inhibit not only proinflammatory cytokines but also neuroprotec-
tive growth factors, e.g., glial-derived neurotrophic factor (14),
brain-derived neurotrophic factor (BDNF), and NT-3 (55). A
recent study showing that the neuroprotection activities of EPO for
hippocampal neurons in vitro depends on the production of BDNF
(56) is directly relevant. In this view, MPSS could suppress EPO-
mediated neurotrophin production, accounting for the deleterious
effects of glucocorticoids in saline-treated animals (i.e., interfering
with endogenously produced EPO and with exogenous EPO).
These explanations for the antagonizing effects of MPSS on the
beneficial effects of EPO require further evaluation.
In sum, these studies show a wide dose- and time window for the
use of EPO in SCI. MPSS appears to negate critical early-phase
actions of EPO. Although further study is required to understand
the effects of multiple dosing of MPSS, prudence dictates that
MPSS or other glucocorticoids be avoided in clinical trials to
determine the efficacy of EPO in human spinal cord disease.
Whether similar neutralizing effects of MPSS occur with other
therapeutics is unknown but should be considered a possibility.
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